drugset / Trial / NCT03810313
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
Timeline
- Start
- 2019-07-03
- Primary completion
- 2021-07-26
- Completion
- 2021-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Brolucizumab | Other / unclassified | 6 mg | Intravitreal |